CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

Biotechnology

Health Care

Therapeutics

CellCentric

This department oversees the chemistry, manufacturing, and controls processes essential for drug development and product quality.

CMC Management

This department oversees the planning, execution, and management of clinical trials to ensure regulatory compliance and participant safety.

Clinical Research

This department focuses on setting the strategic direction and overall leadership of the organization.

Executive Leadership

This department oversees and ensures the effectiveness and quality of clinical processes and operations.

Clinical Operations

This department oversees the strategic direction and decision-making processes of the organization through its board members.

Board Governance

This department focuses on research and development related to cancer biology and its therapeutic pathways.

People (0)

Jobs (0)

Other teams

Clinical Research

Executive Leadership

Clinical Operations

Board Governance

Cancer Biology